MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.530 +0.030 (+2.00%)
Streaming Delayed Price Updated: 1:09 PM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 155,838
Open 1.570
Bid (Size) 1.520 (1,900)
Ask (Size) 1.540 (1,300)
Prev. Close 1.500
Today's Range 1.520 - 1.570
52wk Range 1.120 - 2.570
Shares Outstanding 5,847,955
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical... 
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma ↗
Additional forthcoming biomarker data from human trial expected to further characterize immune pathway activation and its relationship to clinical outcomesU.S.,... 
Via Newsfile

Performance

YTD
+14.2%
+14.2%
1 Month
+26.4%
+26.4%
3 Month
-8.4%
-8.4%
6 Month
-30.5%
-30.5%
1 Year
-6.1%
-6.1%

More News

Read More
News headline image
OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies
Via Newsfile
News headline image
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
Via Newsfile
News headline image
OS Therapies Enters into Warrant Inducement Agreements
Via Newsfile
News headline image
OS Therapies Provides First Half 2026 Corporate Outlook
Via Newsfile
Topics Regulatory Compliance
Market Signals Highlight Next Wave of Immunotherapy Growth (OSTX, IBRX)
Via AB Newswire
News headline image
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
Via Newsfile
News headline image
OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization
Via Newsfile
News headline image
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25
Via Newsfile
News headline image
OS Therapies to Spinoff OS Animal Health into Standalone Public Company
Via Newsfile
News headline image
OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
Via Newsfile
News headline image
Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate ↗
Via Benzinga
News headline image
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting
Via Newsfile
News headline image
OS Therapies to Participate in Fall 2025 Conferences and Events
Via Newsfile
News headline image
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
Via Newsfile
News headline image
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
Via Newsfile

Frequently Asked Questions

Is OS Therapies Incorporated Common Stock publicly traded?
Yes, OS Therapies Incorporated Common Stock is publicly traded.
What exchange does OS Therapies Incorporated Common Stock trade on?
OS Therapies Incorporated Common Stock trades on the New York Stock Exchange
What is the ticker symbol for OS Therapies Incorporated Common Stock?
The ticker symbol for OS Therapies Incorporated Common Stock is OSTX on the New York Stock Exchange
What is the current price of OS Therapies Incorporated Common Stock?
The current price of OS Therapies Incorporated Common Stock is 1.530
When was OS Therapies Incorporated Common Stock last traded?
The last trade of OS Therapies Incorporated Common Stock was at 03/17/26 01:09 PM ET
What is the market capitalization of OS Therapies Incorporated Common Stock?
The market capitalization of OS Therapies Incorporated Common Stock is 8.95M
How many shares of OS Therapies Incorporated Common Stock are outstanding?
OS Therapies Incorporated Common Stock has 9M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story